Clinical Trial Update: Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of ipilimumab, nivolumab, and cabozantinib in refractory cutaneous melanoma was terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• cabozantinib (cabozantinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Providence Health & Services | Conditions: Refractory Cutaneous Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2024-09-19